Apoptosis induced by 1,3,6,7-tetrahydroxyxanthone in Hepatocellular carcinoma and proteomic analysis

Apoptosis

Volumn 17, Issue 8, 2012, Pages 842-851

  Fu, Wei Ming ^a   Zhang, Jin Fang ^a,b   Wang, Hua ^a   Tan, Hong Sheng ^c   Wang, Wei Mao ^b   Chen, Shih Chi ^a   Zhu, Xiao ^d   Chan, Tak Ming ^a   Tse, Ching Man ^a   Leung, Kwong Sak ^a   Lu, Gang ^e   Xu, Hong Xi ^c   Kung, Hsiang Fu ^a,b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

^c SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^d GUANGDONG MEDICAL UNIVERSITY   (China)

^e CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

1,3,6,7 tetrahydroxyxanthone; 14 3 3r; Apoptosis; Hepatocellular carcinoma; P16

Indexed keywords

BETA TUBULIN; NORATHYRIOL; PROTEIN 14 3 3; PROTEIN P16; RETINOBLASTOMA PROTEIN;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; SIGNAL TRANSDUCTION; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION; WESTERN BLOTTING;

14-3-3 PROTEINS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DRUGS, CHINESE HERBAL; EXONUCLEASES; GARCINIA; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HUMANS; LIVER NEOPLASMS; PROTEOME; PROTEOMICS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; XANTHONES;

EID: 84865122683     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-012-0729-y     Document Type: Article

References (38)

1. Poon RT, Fan ST, Lo CM, Liu CL, Liu CL, Ng IO, Wong J (2000) Long-term prognosis after resection of hepatocellular carcinoma associated with hepatitis B-related cirrhosis. J Clin Oncol 18:1094-1101 (Pubitemid 30123788)
2. Wang X, Chen Y, Han QB, Chan CY, Wang H, Liu Z et al (2009) Proteomic identification of molecular targets of gambogic acid: role of stathmin in hepatocellular carcinoma. Proteomics 9:242-253
3. Huang SX, Feng C, Zhou Y, Xu G, Han QB, Qiao CF et al (2009) Bioassay-guided isolation of xanthones and polycyclic prenylated acylphloroglucinols from Garcinia oblongifolia. J Nat Prod 72:130-135
4. Anderson NL, Anderson NG (1998) Proteome and proteomics: new technologies, new concepts, and new words. Electrophoresis 19:1853-1861 (Pubitemid 28392230)
5. Blackstock WP, Weir MP (1999) Proteomics: quantitative and physical mapping of cellular proteins. Trends Biotechnol 17:121-127 (Pubitemid 29348464)
6. Yan G, Li L, Tao Y, Liu S, Liu Y, Luo W et al (2006) Identification of novel phosphoproteins in signaling pathways triggered by latent membrane protein 1 using functional proteomics technology. Proteomics 6:1810-1821
7. Zhang JF, He ML, Dong Q, Xie WD, Chen YC, Lin MC et al (2011) Aqueous extracts of Fructus Ligustri Lucidi enhance the sensitivity of human colorectal carcinoma DLD-1 cells to doxorubicin-induced apoptosis via Tbx3 suppression. Integr Cancer Ther 10:85-91
8. Zhang JF, He ML, Fu WM, Wang H, Chen LZ, Zhu X et al (2011) Primate-specific miRNA-637 inhibits tumorigenesis in hepatocellular carcinoma by disrupting stat3 signaling. Hepatology 54:2137-2148
9. Diao S, Zhang JF, Wang H, He ML, Lin MC, Chen Y et al (2010) Proteomic identification of microRNA-122a target proteins in hepatocellular carcinoma. Proteomics 10:3723-3731
10. Ma Y, Yu J, Chan HL, Chen YC, Wang H, Chen Y et al (2009) Glucose-regulated protein 78 is an intracellular antiviral factor against hepatitis B virus. Mol Cell Proteomics 8:2582-2594
11. Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J Comput Chem 31:455-461
12. Schutte M, Hruban RH, Geradts J, Maynard R, Hilgers W, Rabindran SK et al (1997) Abrogation of the PRb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 57:3126-3130 (Pubitemid 27351723)
13. Aitken A, Collinge DB, van Heusden BP, Isobe T, Roseboom PH, Rosenfeld G et al (1992) 14-3-3 proteins: a highly conserved, widespread family of eukaryotic proteins. Trends Biochem Sci 17:498-501
14. Wang W, Shakes DC (1996) Molecular evolution of the 14-3-3 protein family. J Mol Evol 43:384-398 (Pubitemid 26337547)
15. Obsilová V, Silhan J, Boura E, Teisinger J, Obsil T (2008) 14-3-3 proteins: a family of versatile molecular regulators. Physiol Res 57(Suppl 3):S11-S21
16. Martin H, Patel Y, Jones D, Howell S, Robinson K, Aitken A (1993) Antibodies against the major brain isoforms of 14-3-3 protein. An antibody specific for the N-acetylated amino-terminus of a protein. FEBS Lett 331:296-303 (Pubitemid 23287291)
17. Samuel T, Weber HO, Rauch P, Verdoodt B, Eppel JT, McShea A et al (2001) The G2/M regulator 14-3-3sigma prevents apoptosis through sequestration of Bax. J Biol Chem 276:45201-45206
18. Laronga C, Yang HY, Neal C, Lee MH (2000) Association of the cyclin-dependent kinases and 14-3-3 sigma negatively regulates cell cycle progression. J Biol Chem 275:23106-23112 (Pubitemid 30646202)
19. Ferguson AT, Evron E, Umbricht CB, Pandita TK, Chan TA, Hermeking H et al (2000) High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. Proc Natl Acad Sci USA 97:6049-6054 (Pubitemid 30367521)
20. Suzuki H, Itoh F, Toyota M, Kikuchi T, Kakiuchi H, Imai K (2000) Inactivation of the 14-3-3 sigma gene is associated with 50 CpG island hypermethylation in human cancers. Cancer Res 60:4353-4357 (Pubitemid 32103610)
21. Iwata N, Yamamoto H, Sasaki S, Itoh F, Suzuki H, Kikuchi T et al (2000) Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3 sigma gene in human hepatocellular carcinoma. Oncogene 19:5298-5302
22. Yang HY, Wen YY, Chen CH, Lozano G, Lee MH (2003) 14-3-3 sigma positively regulates p53 and suppresses tumor growth. Mol Cell Biol 23:7096-7107 (Pubitemid 37210993)
23. Yang HY, Wen YY, Lin YI, Pham L et al (2007) Roles for negative cell regulator 14-3-3sigma in control of MDM2 activities. Oncogene 26:7355-7362 (Pubitemid 350115974)
24. Yang H, Wen YY, Zhao R, Lin YL, Fournier K, Yang HY et al (2006) DNA damage-induced protein 14-3-3 sigma inhibits protein kinase B/Akt activation and suppresses Akt-activated cancer. Cancer Res 66:3096-3105
25. Reymond A, Brent R (1995) p16 proteins from melanoma-prone families are deficient in binding to Cdk4. Oncogene 11: 1173-1178
26. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA (1994) Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368:753-756 (Pubitemid 24153417)
27. Stone S, Jiang P, Dayananth P, Tavtigian SV, Katcher H, Parry D et al (1995) Complex structure and regulation of the P16 (MTS1) locus. Cancer Res 55:2988-2994
28. Lukas J, Bartkova J, Rohde M, Strauss M, Bartek J (1995) Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity. Mol Cell Biol 15:2600-2611
29. Li J, Melvin WS, Tsai MD, Muscarella P (2004) The nuclear protein p34SEI-1 regulates the kinase activity of cyclin-dependent kinase 4 in a concentration-dependent manner. Biochemistry 43:4394-4399 (Pubitemid 38445661)
30. Sugimoto M, Nakamura T, Ohtani N, Hampson L, Hampson IN, Shimamoto A et al (1999) Regulation of CDK4 activity by a novel CDK4-binding protein, p34 (SEI-1). Genes Dev 13: 3027-3033
31. Russo AA, Tong L, Lee JO, Jeffrey PD, Pavletich NP (1998) Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a. Nature 395:237-243 (Pubitemid 28447541)
32. Kaldis P, Ojala PM, Tong L, Mäkelä TP, Solomon MJ (2001) CAK-independent activation of CDK6 by a viral cyclin. Mol Biol Cell 12:3987-3999 (Pubitemid 34001087)
33. Clark PA, Llanos S, Peters G (2002) Multiple interacting domains contribute to p14ARF mediated inhibition of MDM2. Oncogene 21:4498-4507 (Pubitemid 34785726)
34. Pomerantz J, Schreiber-Agus N, Liégeois NJ, Silverman A, Alland L, Chin L et al (1998) The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92:713-723 (Pubitemid 28155311)
35. Chitpatima ST, Makrides S, Bandyopadhyay R, Brawerman G (1998) Nucleotide sequence of a major messenger RNA for a 21 kilodalton polypeptide that is under translational control in mouse tumor cells. Nucleic Acids Res 16:2350
36. Tuynder M, Susini L, Prieur S, Besse S, Fiucci G, Amson R et al (2002) Biological models and genes of tumor reversion: cellular reprogramming through tpt1/TCTP and SIAH-1. Proc Natl Acad Sci USA 99:14976-14981 (Pubitemid 35334595)
37. Arcuri F, Papa S, Carducci A, Romagnoli R, Liberatori S, RipapRbelli MG et al (2004) Translationally controlled tumor protein (TCTP) in the human prostate and prostate cancer cells: expression, distribution, and calcium binding activity. Prostate 60:130-140 (Pubitemid 38758578)
38. Liu H, Peng HW, Cheng YS, Yuan HS, Yang-Yen HF (2005) Stabilization and enhancement of the antiapoptotic activity of mcl-1 by TCTP. Mol Cell Biol 25:3117-3126 (Pubitemid 40464314)